Sign In
Buy GRCL
$10.25
+0 (+0%)
At Close: May 20, 2024
Gracell Biotechnologies Acquisition Completed
08:45am, Thursday, 22'nd Feb 2024
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceu
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
07:45am, Tuesday, 20'th Feb 2024
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceu
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma Further expands clinical d
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?
01:32pm, Wednesday, 03'rd Jan 2024
Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Gracell Biot
Yes Virginia, There Is a Santa Claus Rally
06:47pm, Tuesday, 26'th Dec 2023
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
04:29am, Tuesday, 26'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Gracell Biotechnologies Inc. (NASDAQ: GRCL) to AstraZeneca is fair to Gracell shareholder
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
02:01am, Tuesday, 26'th Dec 2023
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical compan
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
02:00am, Tuesday, 26'th Dec 2023
Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprieta
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why
10:32am, Thursday, 21'st Dec 2023
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently o
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, a
Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months
Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade
11:17am, Monday, 11'th Dec 2023
The mean of analysts' price targets for Gracell Biotechnologies Inc. Sponsored ADR (GRCL) points to a 127.8% upside in the stock. While this highly sought-after metric has not proven reasonably effect
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells
What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?
01:31pm, Thursday, 23'rd Nov 2023
Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
